Non-interventional Study of Patients with Transthyretin (ATTR) Amyloidosis - MaesTTRo

Study identifier:D8450R00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Transthyretin (ATTR) Amyloidosis

Medical condition

Transthyretin Amyloidosis

Phase

Phase 4

Healthy volunteers

No

Study drug

Treatment of transthyretin (ATTR) amyloidosis in observational study setting

Sex

All

Estimated Enrollment

1600

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 28 Jun 2024
Estimated Primary Completion Date: 27 Jun 2031
Estimated Study Completion Date: 27 Jun 2031

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

ICON plc

Inclusion and exclusion criteria